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A B S T R A C T
The glioblastoma (GBM) immune microenvironment is highly heterogeneous, and microglia may represent
30–70% of the entire tumor. However, the role of microglia and other specific immune populations is poorly
characterized. Activation of mTOR signaling occurs in numerous human cancers and has roles in microglia-
glioma cell interactions. We now show in human tumor specimens (42 patients), that 39% of tumor-associated
microglial (TAM) cells express mTOR phosphorylated at Ser-2448; and similar mTOR activation is observed
using a human microglia-glioma interaction paradigm. In addition, we confirm previous studies that microglia
express urea and ARG1 (taken as M2 marker) in the presence of glioma cells, and this phenotype is down-
regulated in the presence of a mTOR inhibitor. These results suggest that mTOR suppression in GBM patients
might induce a reduction of the M2 phenotype expression in up to 40% of all TAMs. Since the M2 profile of
microglial activation is believed to be associated with tumor progression, reductions in that phenotype may
represent an additional anti-tumor mechanism of action of mTOR inhibitors, along with direct anti-proliferative
activities.
1. Introduction
Glioblastoma (GBM - grade IV glioma) is the most aggressive pri-
mary brain tumor, characterized by a high rate of therapeutic failures
despite aggressive treatments, and a poor prognosis. Tumor classifica-
tion is based on malignancy, nuclear atypical and infiltration of the
surrounding brain parenchyma. Unfortunately, the tumor is often di-
agnosed once the patients become symptomatic, at which time the le-
sion is already widely extended. The gold standard of therapy, estab-
lished over a decade ago, consists of fractionated radiotherapy in
combination with classical chemotherapy with temozolomide; how-
ever, in almost all cases, chemotherapeutic resistance arises and re-
currence is common after initial therapy (Weller, 2018; Lu et al., 2018).
The clinical success of cancer immunotherapies targeting T-cell
immune checkpoint receptors PD-1/PD-L1 has demonstrated the im-
portance of immune-evasion as a hallmark of cancer. On the side of
innate immune responses, the recent preclinical and clinical develop-
ment of novel CCR2 antagonists to control the trafficking of
macrophage-monocyte lineage belongs to the same conceptual frame-
work (Liang et al., 2018; Amin et al., 2018; Tsutsumi-Kuroda et al.,
2018). These immunotherapeutic drugs include antibody-drug con-
jugates, peptide vaccines, autologous infusions of modified chimeric
antigen receptor-expressing T cells, autologous dendritic cell vaccines,
oncolytic viruses, immune-stimulatory viruses, checkpoint blockade
inhibitors, and drugs acting on innate immune cells (Miyauchi and
Tsirka, 2018).
The GBM immune microenvironment is heterogeneous and can
differ in GBM subtypes (Chen and Hambardzumyan, 2018). Although
manipulation of the tumor microenvironment was shown to be able to
repress GBM tumor progression (Arbab et al., 2017), the role of specific
immune populations remains poorly characterized. Microglia are the
principal resident immune cells in the central nervous system (CNS) and
are thought to be versatile players in both inflammatory and physio-
logical contexts. Although the past decade has seen important progress
in the understanding of multi-tasking microglia in GBM pathology, the
relative importance of microglia at different disease stages and how
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microglia could be targeted for optimal therapeutic efficacy remain
largely enigmatic. Glioma associated microglia (GAMs) constitute the
largest portion of tumor infiltrating cells, contributing between 30 and
70% to the glioma mass (Wood and Morantz, 1979; Roggendorf et al.,
1996; da Fonseca and Badie, 2013). Different profiles of activation co-
exist in the same tumor, depending on GAM location or stage of disease
(Dello Russo et al., 2017). In particular, GAMs are exposed to factors
inducing them to produce cytokines and chemokines, which contribute
to tumor growth and to maintain a pro-tumorigenic, im-
munosuppressed microenvironment. Therefore, a bi-directional inter-
action exists between microglia and GBM. In this context, we previously
investigated the in vitro interactions between rat microglia and C6
glioma cells (Lisi et al., 2014a). Exposure to conditioned media ob-
tained from C6 cells taken under baseline conditions induced a pre-
dominant M2-like phenotype in the microglia. Conversely, if C6 cells
were exposed to a medium containing pro-inflammatory stimuli, the
subsequent exposure of microglia to such medium was followed by a
shift towards an M1-like phenotype (Lisi et al., 2014a). In addition, we
investigated the status of microglia/macrophage activation in surgical
specimens from 41 patients diagnosed with grade IV GBM. For each
patient we analyzed both the center of the tumor and the surrounding
parenchyma. Four different markers, namely IBA-1, CD163, iNOS and
ARG-I were investigated and we showed that M2 markers (in particular
CD163) rather than M1 markers could be envisioned as a prognostic
marker (Lisi et al., 2017a).
The phospho-inositide 3 kinase (PI3K)/protein kinase B (AKT)/
mammalian target of rapamycin (mTOR) pathway is a well-investigated
signaling pathway that regulates diverse cellular functions including
proliferation, metabolism and transcription (Tee, 2018). Activation of
mTORC1 is observed in numerous human cancers due to gain-of-func-
tion mutations in oncogenes (PI3K, AKT or Ras) and/or loss-of-function
mutations in tumor suppressors (PTEN, LKB1, or TSC1/2) (Foster and
Fingar, 2010). In addition, a direct role of mTOR in the modulation of
glial functions has been described. Data from ourselves and other
groups support the notion that mTOR is involved in glial pro-in-
flammatory activation (Dello Russo et al., 2009; Lisi et al., 2011) and in
microglia-glioma interactions (Lisi et al., 2014b). In an in vitro rat
model, we showed that the inhibition of mTOR polarizes glioma-acti-
vated microglial cells towards the M1 phenotype, and in parallel pre-
vents the induction of the M2 status that promotes tumor growth (Lisi
et al., 2014b). Although the relevance of mTOR in glioma biology is
now well established, initial studies with mTORC1 inhibitors, such as
rapamycin (RAPA) and its analogs, showed limited efficacy in clinical
trials (Martelli et al., 2018). Despite such initial failures, newer mTOR
inhibitors are being investigated; ClinicalTrials.gov currently lists 478
ongoing studies on mTOR and cancer, 28 out of them being focused on
glioma. Most of these trials are testing ATP-competitive mTOR in-
hibitors, alone or in combination with monoclonal antibodies; this
strategy targets both GBM cells and GAM functions, thereby raising the
need for further research into this area.
In the present work, we adopted two different approaches, i.e.
human tumor specimens and human cell models, to characterize the
activation of the mTOR pathway in GAMs. In particular, using im-
munostaining analysis of surgical GBM specimens obtained from 42
patients, we evaluated phosphorylated-mTOR expression and localiza-
tion to microglial cells and using three human cell lines, we in-




Cell culture reagents [Dulbecco's modified Eagle's medium (DMEM),
DMEM-F12 and Fetal calf serum (FCS)] were from Invitrogen
Corporation (Paisley, Scotland). Antibiotics were from Biochrom AG
(Berlin, Germany). Bacterial endotoxin LPS (Salmonella typhimurium)
was from Sigma–Aldrich (St. Louis, MO, USA). The rat recombinant
interferon-γ (IFNγ) was purchased from Endogen (Pierce
Biotechnology, Rockford, IL, USA). The human recombinant interleukin
1β (IL1β), human IFNγ and recombinant human Tumor necrosis factorα
(TNFα) were purchased from R&D System. β-actin (clone AC-74) mouse
monoclonal antibody was from Sigma Aldrich; rabbit polyclonal anti-
phospho [ser-2448] mTOR and rabbit polyclonal anti-total mTOR were
purchased from Novus Biological (Littleton, CO, USA); mouse mono-
clonal p70 S6 was purchased from Santa Cruz Biotechnology; rabbit
polyclonal 4EBP1 was purchased from Bethyl Laboratories; monoclonal
rabbit Tuberin/TSc2 was purchased from Cell Signaling Technology,
goat monoclonal AIF-1/Iba1 was purchased from Novus Biological.
Arginase I (E−2) mouse monoclonal antibody was purchased from
Santa Cruz Biotechnology.
2.2. Cell cultures
The human microglia cell line (CHME-5; RRID:CVCL_5J53) was
kindly provided by professor Pierre Talbot (Janabi et al., 1995). Human
U87MG and T98G glioma cell lines were kindly provided by professor
Grazia Graziani (Tor Vergata University- Rome). CHME-5, U87MG and
T98G cells were grown in DMEM containing 10% FCS and antibiotics
and studies carried out at a low concentration of FCS (1%). Cells were
passed twice a week and plated for experiments at 2×104 cells/well.
All the experiments received institutional approval.
Conditioned media from activated glioma cells was generated fol-
lowing a protocol which removed the proinflammatory stimulus from
the medium. Briefly, in preliminary experiments glioma cells were in-
cubated in the presence of mixture of cytokines (10 ng/ml TNFα, 10 ng/
ml IL1β, 10 UI/ml hIFNγ (TII) for 4, 8 or 24 h (Fig. 3). Proinflammatory
mRNA levels were evaluated by real time quantitative PCR (qPCR).
Based on the results, the glioma-CM were prepared as follows:
A) B-CM: 4 h incubation in plain medium, followed by 3 washes with
phosphate buffered saline (PBS) and addition of fresh plain medium
for 24 h. After this second period of incubation, the CM was col-
lected, centrifuged to remove cellular debris and stored as B-CM.
B) PS-CM: 4 h incubation with TII, followed by 3 washes with PBS and
addition of fresh plain medium for 24 h. After this second period of
incubation, the CM was collected, centrifuged and stored as PS-CM.
Both CM were stored at −80 °C until the experiments on CHME-
5 cells were performed.
A flow chart of the studies shows the experimental design (Scheme
1).
2.3. Viability assay
The cell viability was measured using a specific luminescence kit:
CellTiter-Glo® Luminescent Cell Viability Assay (Promega). Cell mor-
tality was detected using a specific fluorescence kit: RealTime-Glo™ MT
Cell Viability Assay (Promega). The assays were carried out according
to the manufacturer's instructions.
2.4. Nitrite assay
iNOS activity was assessed indirectly by measuring nitrite accu-
mulation in the incubation media. Briefly, an aliquot of the cell culture
media (80 μL) was mixed with 40 μL Griess Reagent (Sigma-Aldrich)
and the absorbance measured at 550 nm in a spectrophotometric mi-
croplate reader (PerkinElmer Inc., MA, USA). A standard curve was
generated during each assay in the range of concentrations 0–100 μM
using NaNO2 (Sigma-Aldrich). In this range, the assay was linear and
the minimum detectable concentration of NaNO2 was ≥3.12 μM. The
protein content in each sample was determined by Bradford's method
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(Biorad, Hercules, CA, USA) using bovine serum albumin as standard.
2.5. Urea assay
Urea levels in CHME-5 cells were detected by the QuantiChrom Urea
Assay kit (BIOassay System, Hayward, CA, USA), used according to the
manufacturer's instructions. Briefly after 48 h of incubation with the
test substances, an aliquot of cell culture media (50 μl) was mixed with
200 μL Urea Reagent (Bioassay system) and the absorbance measured at
430 nm in a spectrophotometric microplate reader (PerkinElmer Inc.,
MA, USA). A standard curve was generated during each assay in the
range of concentrations 0–100 μg/ml using Urea as standard. In this
range, standard detection was linear and the minimum detectable
concentration of Urea was 3.12 μg/ml. The protein content in each
sample was determined by Bradford's method (Biorad, Hercules, CA,
USA) using bovine serum albumin as standard.
2.6. mRNA analysis in real time PCR
Total cytoplasmic RNA was extracted using the RNeasy Micro kit
(Qiagen, Hilden, Germany), which included 15min DNase treatment.
RNA concentration was measured using the Qubit™ RNA HS Assay Kit
(Thermo Fisher Scientific). Aliquots (0.5 μg) of RNA were converted to
cDNA using random hexamer primers. Quantitative changes in mRNA
levels were estimated by real time PCR using the following cycling
conditions: 35 cycles of denaturation at 95 °C for 20 s; annealing and
extension at 60 °C for 20 s; using the Brilliant III Ultra-Fast SYBR® Green
QPCR Master Mix (Stratagene, La Jolla, CA, USA). PCR reactions were
carried out in a 20-μL reaction volume in Ariamx real time PCR
machine (Stratagene). Primers used for the evaluation of gene expres-
sion are reported in Table 1. Relative mRNA concentrations were cal-
culated from the take-off point of reactions (threshold cycle, Ct) using
the comparative quantitation method provided by Stratagene software
and based upon the -ΔΔCt method. This analysis approximates a given
sample's target mRNA (e.g. IL6) level relative to the mean of the target
mRNA levels in untreated controls (‘‘calibrator’’ value), thus permitting
statistical analysis of deviation from the mean even among the controls.
Ct values for α-tubulin expression served as a normalizing signal. In
each assay, the PCR efficiency was also calculated using serial dilution
of one experimental sample; efficiency values between 94 and 98%
were found for each primer set and taken into account for the com-
parative quantitation analysis (Dello Russo et al., 2009).
2.7. IL1β, IL6 and PGE2 quantification
IL1β, IL6 and PGE2 levels in the incubation medium were detected
using a specific Enzyme Immunoassay kit (EIA) for PGE2
(ELABscience), and a specific enzyme-linked immunosorbent assay
(ELISA) for IL1β and IL6 (R&D System). The assays were carried out
according to the manufacturer's instructions.
2.8. Western immunoblot
The cells were lysed in RIPA buffer (1 mM EDTA, 150mM NaCl, 1%
igepal, 0.1% sodium dodecyl sulfate, SDS, 0.5% sodium deoxycholate,
50mM Tris–HCl, pH 8.0) (Sigma-Aldrich) containing protease inhibitor
cocktail diluted 1:250 (Sigma–Aldrich). The protein content in each
sample was determined by Bradford's method (Biorad, Hercules, CA,
Scheme 1. Metodological flow chart of the study.
Table 1
Primers used for the evaluation of gene expression.
Genes Forward Reverse Product length
ARG1 TTCTCAAAGGGACAGCCACG AGCACCAGGCTGATTCTTCC 272
ARG2 ACCTCAGAGGAAGAGGCGAA AAATGTCCCCATTAAGGCAGT 276
COX2 TG CTG GCA GGG TTG CTGGTGGTA CAT CTG CCT GCT CTG GTC AAT CGA A 86
IL10 GGCACCCAGTCTGAGAACAG CGCCTTGATGTCTGGGTCTT 255
IL1β AGC CAT GGC AGA AGT ACC GT TCC ATG GCC ACA ACA ACT GA 219
IL6 GGC TCA TTC TGC CCT CGA GCC GGA CCG AAG GCG CTT GTG GAG 100
iNOS CTGCATGGAACAGTATAAGGCAAA C CAGACAGTTTCTGGTCGATGTCATGA 230
Raptor GGT GCT GTT AAG CCA AGT GC TGT TCA GCT GGC ATG TAG GG 279
Rictor TGG GCG AGG TTT CCG GT GTC ATT CCG CCC TCG TAC TC 99
TGFβ CATG GAG CTG GTG AAA CGG A CGG GTG ACT TCT TTG GCG TA 219
Tubuline CCC TCG CCA TGG TAA ATA CAT ACT GGA TGG TAC GCT TGG TCT 110
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USA) using bovine serum albumin as standard. A 100 μg aliquot of
protein was mixed 1:2 with 2X Laemmli Buffer (Biorad), boiled for
5min, and separated through 10% polyacrylamide SDS gels. Apparent
molecular weights were estimated by comparison to colored molecular
weight markers (Sigma Aldrich). After electrophoresis, proteins were
transferred to polyvinylidene difluoride membranes by semi-dry elec-
trophoretic transfer (Biorad). The membranes were blocked with 10%
(w/v) low-fat milk in TBST (10 mMTris, 150 mMNaCl, 0.1% Tween-20,
pH 7.6) (Biorad) for 1 h at room temperature, and incubated in the
presence of the primary antibody overnight with gentle shaking at 4 °C.
Primary antibodies for rabbit Polyclonal anti-phospho mTOR (NB600-
607-novus), rabbit polyclonal anti-mTOR (NB-novus), mouse mono-
clonal anti β-actin clone AC-74 (A531-Sigma), mouse monoclonal anti
p-p70 S6 kinase α (A-6) (sc-8416-Santa Cruz), rabbit Polyclonal anti-
4EBp1 (A300-501A-Bethyl), and rabbit monoclonal anti Tuberin/TSC
(D93F12) (4308 – Cell Signaling) were used at the final concentration
of 1:1000. Primary antibodies were removed, membranes washed 3
times in TBST, and further incubated for 1 h at room temperature in the
presence of specific secondary antibody diluted 1:15,000. Following
three washes in TBST, bands were visualized by incubation in ECL re-
agents (GE Healthcare) and exposure to Hyperfilm ECL (GE Healthcare
NY, USA). The same membranes were washed 3 times in TBST, blocked
with 10% (w/v) low-fat milk in TBST for 1 h at room temperature and
used for β-actin immunoblot.
2.9. Immunostaining
Cover glasses of 13mm of diameter were coated with Collagen I
0,1 mg/ml or Poli-L-lysine 50ug/ml for 1 h at 37 °C, after that three
washes in PBS with calcium and magnesium were needed and used to
seed the CHME-5 at 20000 cells per well concentration. After 24 h from
the treatment, cells were blocked with PAF at 4% concentration in PBS
with calcium and magnesium for 20min at room temperature. After
three washes in PBS with calcium and magnesium, cells were blocked
with BSA and incubated in presence of primary antibody. The incuba-
tion time was overnight for ARG1 1:50; after three washes in PBS with
calcium and magnesium in gentle shaking, cells were incubated with
secondary antibody (anti-mouse) for 1 h and mounted with Vectashield
with DAPI (Vector Laboratories).
2.10. Patients and specimens
We enrolled 42 adults [mean age 60.51 (34–79), 27 males/15 fe-
males], who underwent surgery for primary GBM at the Neurosurgery
Department, Fondazione Policlinico Gemelli” (Rome, Italy), from
March 2005 to September 2011. Diagnosis of GBM was established on
histological examination according to the WHO classification (grade IV)
of tumors of the CNS. In all cases a total tumor removal was achieved,
allowing us to obtain tissues samples from both the tumor and the
surrounding macroscopic normal brain tissue (between 1 cm and 2 cm
from the tumor border; larger resections were performed in tumors that
grew far from eloquent areas). The demographic characteristics for
single patient are reported in Table 2. All patients provided written
consent to use their specimens for research and the research proposal
was approved by the local ethics Ethical Committee (Lisi et al., 2017a).
2.11. Tissue preparation and immunohistochemistry
Human tumor tissue obtained from surgical resection of patients
with grade IV GBM were fixed in 4% paraformaldehyde in 0.1 M
phosphate buffer pH 7.6 overnight at 4 °C. Dehydration of tissue was
through a series of 80%, 95% ethanol one hour each followed by 100%
ethanol overnight. Two 100% xylene washes were done for 1 h each
and then 1 h in 60 °C Paraplast Plus (Tyco/Healthcare, Mansfield, MA).
After a change of Paraplast Plus, tissue was incubated in a 60 °C vacuum
oven for 2 h prior to placing in molds to cool and solidify. Sections,
3–4 μm thick, were cut and collected on the superfrost plus slides
(Fisher). The PT Link (Dako) was used to deparaffinize and rehydrate
the sections and unmask antigen sites. Slides were immersed in 10mM
citrate buffer, pH 6.0, for 10min at 97 °C and then cooled and washed
in PBS or TBS. Endogenous peroxidase activity was inhibited by in-
cubating the slides with Peroxide Block (ScyTek Laboratories, Utah,
USA) for 7min. At this time, point slides washed with PBs underwent
single staining procedures, whereas slides washed with TBS underwent
double staining procedures.
2.12. Single-staining
After washing in distilled water and then in PBS, slides were in-
cubated with Avidin/Biotin Blocking System (Spring) and washed 3
times in PBS. Nonspecific binding was blocked by 5min incubation
with the Super Block Solution (ScyTek Laboratories, Utah, USA).
Sections were incubated for 30min at room temperature with rabbit
anti-human mTOR polyclonal antibody (Novus Biologicals) 1:100, or
over-night at 4 °C with goat anti-human Iba1 polyclonal antibody
(Novus Biologicals) 1:250. Sections were washed extensively with PBS
and subsequently treated with the Ultra Tek HRP Anti-Polyvalent kit
(ScyTek Laboratories). Finally, after 3 washes in PBS, sections were
treated with 3,3′-diaminobenzidine (ScyTek Laboratories) as chro-
mogen, contrasted with Hematoxylin and mounted.
2.13. Double-staining
The PT Link (Dako) was used to deparaffinize and rehydrate the
sections and unmask antigen sites. Slides were immersed in 10mM ci-
trate buffer, pH 6.0, for 10min at 97 °C and then cooled and washed in
TBS. Endogenous peroxidase activity was inhibited by incubating the
slides with Peroxide Block (ScyTek Laboratories, Utah, USA) for 7min.
After washing in distilled water and then in TBS, nonspecific binding
was blocked by 10min incubation with Background Punisher (Biocare-
Medical). Sections were incubated for 30min at room temperature with
Rabbit Anti-Human mTOR polyclonal antibody (Novus Biologicals)
1:100 and over-night at 4 °C with Goat Anti-Human Iba1 polyclonal
antibody (Novus Biologicals) 1:250. Sections were washed extensively
in TBS and subsequently incubated with the MACH 2 Rabbit HRP-
Polymer (Biocare-Medical) for mTOR and with Ultratek HRP kit
(ScyTek Laboratories) for Iba1. Finally, after 3 washes in TBS, sections
were treated with 3,3′-diaminobenzidine (Biocare-Medical) as chro-
mogen for IBA1 and with Vina Green (Biocare-Medical) as chromogen
for p-mTOR and then contrasted with Hematoxylin and mounted.
2.14. Immunostaining analysis
Two examiners who were blinded as to the antibody used evaluated
staining of human specimens. Both qualitative and quantitative ana-
lyses were carried out. For qualitative analysis the intensity of staining
was evaluated. In particular, staining was scored on a scale from 0 to 5
where score 0 indicates no significant staining, score 1 very low
staining, score 2 low staining, score 3 significant staining, score 4 strong
staining and score 5 very strong staining. For quantitative analysis, the
number of phospho-mTOR+, IBA1+, or both phospho-mTOR+ and
IBA1+ cells were counted in at least 50 cells total. In particular, two
blinded examiners have examined three different areas of the same
slides and have counted 50 cells that included the number of positive
cells for each antibody, the number of positive cells for both antibodies
and the number of negative cells (Atzori et al., 2017). In total, the
average of six counts was reported as percentage.
2.15. Statistical analyses
Statistical comparison of the differences between pairs of groups
was performed by Student's t-test. For multiple comparisons ANOVA
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analysis, followed by Bonferroni's post-test or Sidak's test, was used.
Statistical significance was determined at α=0.05 level. Differences
were considered statistically significant when p < 0.05.
3. Results
3.1. mTOR in human glioma specimens
We enrolled 42 patients diagnosed with GBM IV (Table 2). For each
patient, we were able to examine glioma specimens as well as the tissue
surrounding the tumor by 1–2 cm (periphery). More than 35% of the
cells within the glioma tissue and more than 25% of the peripheral cells
showed mTOR activation, indicated by phosphorylation at Ser2448.
Although the percent of phospho-mTOR-activated positive cells was
higher within the tumor, we found no difference in staining intensity
between tumor and peripheral tissues (Fig. 1). In addition, in a sub-
group of 15 patients showing a higher percentage of phospho-
mTOR + cells (39% on average), we carried out a double staining for
phospho-mTOR and IBA1 (Fig. 2), a marker of microglia-macrophage
cell type. Within the tumor, about 9% of all cells were phospho-
mTOR + microglia-macrophages compared to 4.4% within the tissue
surrounding the tumor. Looking at IBA1+ cells, we found that about
22% of cells in the glioma specimens were microglia-macrophages; 39%
out of these cells are IBA1+ cells expressing phosphorylated-mTOR.
Conversely, in periphery of the tumor, 15% of cells are microglia-
macrophages, 21% out of these cells express phospho-mTOR (Fig. 2).
3.2. Characterization of U87MG and T98G glioma cell lines
Two different human glioma cell lines, U87MG and T98G, were
used to examine their responses to an inflammatory stimulus. Cells
were exposed to a mixture of pro-inflammatory cytokines: 10 ng/ml
TNFα, 10 ng/ml IL1β, 10 UI/ml IFNγ (TII), after which gene expression
was evaluated at different time points (4, 8 and 24 h). IL1β, IL6 and
COX2 was significantly increased by TII, with maximal levels at 8 h
after which expression decreased (Fig. 3). In contrast, TGFβ and ARG2
expression was not affected by pro-inflammatory stimuli. Neither iNOS,
IL10 nor ARG1 mRNAs were detectable either before or after pro-in-
flammatory stimulation (data not shown).
Based on these results as well as previous data (Lisi et al., 2014a),
we prepared glioma conditioned medium (CM) by pre-incubating
glioma cells for 4 h with TII or plain medium as control. After pre-in-
cubation, cells were carefully washed and incubated for a further 24 h
in plain medium only to generate basal-conditioned medium (B-CM) or
Table 2
Demographic characteristic of GBM patients.
GBM patients Tumor location Primary (P)
Recurrent (R)
Overall survival (months) WHO classification Tumor Peryphery
1 NAa P 13 IV -b −/+
2 Temporal P 19 IV +++ ++
3 Temporal P 60 IV +++ +++
4 Frontal R NA IV + +
5 Frontal P 7 IV −/+ −/+
6 NA P NA IV - +
7 Frontal P 15 IV +++ +
8 Frontal P 2 IV +++ −/+
9 Temporal P 4 IV +++ +
10 Occipital P 33 IV ++ +++
11 Temporal P 14 IV - -
12 NA P NA IV + +
13 NA R NA IV ++ ++
14 Temporal P 53 IV + -
15 Parietal P 53 IV - −/+
16 NA P 9 IV - −/+
17 Frontal P NA IV - −/+
18 Frontal P NA IV + +
19 Tempo-Parietal R 53 IV +++ +
20 Temporal P C IV - +
21 NA P NA IV + −/+
22 Temporal P NA IV −/+ +++
23 Parietal P 6 IV + -
24 NA P NA IV - +
25 Temporal P NA IV ++ +
26 NA R NA IV +++ +
27 Frontal R NA IV ++ +
28 Occipital P NA IV ++ ++
29 NA P NA IV ++ +
30 Temporal P NA IV + −/+
31 NA P NA IV +++ +
32 Temporal P NA IV + +
33 Temporal P 6 IV - +
34 NA P NA IV −/+ -
35 Frontal P 12 IV −/+ +++
36 Fronto-temporal P NA IV - +
37 Occipital P 8 IV +++ +
38 Frontal P NA IV ++ ++
39 Temporal P NA IV +++ +
40 NA P 38 IV ++ +++
41 NA R 24 IV +++ ++
42 Frontal P 12 IV ++ ++
a NA: not available.
b The number of positive mTOR cells was counted in a total of 50 cells. mTOR staining was scored as percentage of positively stained cells: -, ≤10%; −/+,
11–25%; +, 26–50%; ++, 51–75%; +++,>75%.
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pre-stimulated conditioned medium (PS-CM).
To characterize the CMs, we measured levels of end-products of the
above genes, namely IL1β, IL-6, PGE2, urea and NO, in the incubation
medium. We found that NO (expressed as nitrite levels) was un-
detectable in either B-CMs or PS-CMs obtained from either U87MG or
T98G cells (not shown). In contrast, significant urea levels could be
detected at baseline both in T98G CMs (1 μg/ml on average) and in
U87MG CMs (3 μg/ml on average), but those levels were not different
when the U87MG or T98G were pre-stimulated with the mixture of
cytokines (data not shown). We observed significant 1.5-fold, 4-fold
and 5-fold increases in PGE2, IL6 and IL1β levels, respectively, in
U87MG PS-CM compared to B-CMs (Fig. 4). In T98G PS-CM we also
found a 3-fold and 6-fold increase in IL1 β and IL6 levels, respectively,
as compared to B-CMs, whereas no change was observed in PGE2 levels
(Fig. 4).
3.3. Effects of B-CM and PS-CM obtained from glioma cell lines on human
microglia CHME-5 cells
We next conducted a series of experiments in which the human
microglia CHME-5 cells were exposed to CMs. Cells were incubated
with graded concentrations of CMs (i.e. 25% CM + 75% plain medium,
50% CM + 50% plain medium, 100% CM) over a period of 0–72 h
(Fig. 5). CHME-5 cell growth in plain medium reached a peak within
16–24 h, and remained stable up to up to 48 h; thereafter, an increase in
the number of dead cells was observed (Fig. 5A). This growth profile
remained unchanged when the percent of CMs in the media was in-
creased, with 2 exceptions: at all times tested, 100% B-CM from
U87MG, but not T98G cells increased the total number of live cells,
whereas an increase in lethality was observed after exposure to 100%
PS-CM from T98G cells (Fig. 5B–C). We found no dose-dependent effect
of CM on cell growth; however, a dose-dependent effect was observed
on lethality induced by PS-CM from T98G cells (not shown). Because of
the increase in lethality observed after 48 h of incubation, all sub-
sequent experiments were carried out between 0 and 48 h.
To investigate the phenotypic profile induced in CHME-5 cells by
the different CMs, we measured levels of urea and NO released in the
medium, as markers of L-arginine metabolism through the ARG/NOS
pathways, as well as expression of TNFα, iNOS, TGFβ and IL10 mRNAs.
We found that both B-CM and PS-CM elicited dose-dependent increases
in urea levels, which reached statistical significance compared to plain
medium from 50% of CMs from T98G cells, and at 100% of CMs from
U87MG cells (Fig. 6). On the contrary, we found no difference in NO
levels compared to controls, nor any change in iNOS mRNA levels, or in
any of the other genes tested (not shown).
Fig. 1. Evaluation of mTOR pathway in GBM specimens. Panel A shows a re-
presentative image of phospho-mTOR staining in GBM sample (magnitude 40x),
Panel B shows a representative image of phospho-mTOR staining in periphery
around the tumor (magnitude 40x). Red arrow shows positive cells; yellow
arrow shows negative cells. Panel C shows the percentage of cells expressing
phospho-mTOR, whereas panel D shows the average of intensity score of
phospho-mTOR positive cells.
Fig. 2. Evaluation of microglia-macrophages expressing phospho-mTOR. Panel
A shows a representative image of phospho-mTOR and IBA1 double staining in
glioma specimens. Brown arrow shows IBA1 positive cells, green arrow shows
phospho-mTOR positive cells, and black arrow shows phospho-mTOR and IBA1
positive cells. Panel B shows the percent of microglia-macrophage phospho-
mTOR+ expressing in GBM specimens (black box) and in periphery (grey box).
Fig. 3. Evaluation of pro-inflammatory gene ex-
pression elicited by cytokines in glioma cell lines.
Panel A, B and C show time-dependent up-regulation
of IL-1β, IL-6 and COX2 gene expression respectively
in U87MG (blue line) and in T98G (red line).
*,**,***,****p < 0,05, p < 0,01, p < 0,001 or
p < 0,0001 respectively T98G vs U87MG in each
time point. Two-way ANOVA analysis was carried
out.
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Moreover, we sought to investigate the effects of CMs on CHME-
5 cells that were previously stimulated with TII for 4 h; indeed, such
pre-stimulation drives CHME-5 cells into an activated M1 profile (Lisi
et al., 2017b). Under these conditions, we found significant change in
urea levels elicited by T98G CMs (Fig. 7), however by comparing the
urea releases promoted by all CMs into not pre-stimulated cells (or pre-
treated with medium) versus cells pre-treated with TII, all CMs sig-
nificantly increase urea releases (Fig. 7). In contrast to non-prestimu-
lated cells, all CMs significantly increased iNOS mRNA levels in CHME-
5 cells that were prestimulated with TII for 4 h (Fig. 8). The iNOS mRNA
levels were increased after 4 h stimulation with CMs, but after longer
exposure times (i.e. 24 or 48 h), increases were no longer observed.
After 48 h incubation, the NO levels were increased by pre-treatment
with TII (Fig. 8C), but were consistently reduced by the presence of any
CMs. Taken together the data suggest that CMs induce a M2 profile in
both resting microglia (Fig. 6) and in pre-stimulated M1 microglia
(Figs. 7 and 8), although in the latter with a transient response.
3.4. Involvement of mTOR pathway in glioma-microglia interaction
We next tested if the mTOR pathway is activated in human micro-
glia after exposure to human glioma-derived CMs. We found that both
T98G B-CM and PS-CMs, but not U87MG CMs, significantly increased
phosphorylation of mTOR at Ser2448 with respect to controls after 2-h
incubation periods (Fig. 9A). In parallel, mTOR downstream factor
4EBP1 was significantly modified by B-CMs (Fig. 9B). Similarly, an-
other mTOR downstream factor, p-P70S6k was significantly increased
in the presence of all CMs (Fig. 9C). We also looked at the mechanisms
of mTOR activation; interestingly, the upstream factor TSC2 was sig-
nificantly decreased in the presence of CMs (Fig. 10).
Fig. 4. Evaluation of pro-inflammatory products in
CM obtained after pre-stimulation with cytokines
challenge. Panel A, B and C show the level of IL-1β,
IL-6 and PGE2. *, ***p < 0,05 or p < 0,001 re-
spectively vs U87 MG control or °, °°°p < 0,05 or
p < 0,001 respectively vs T98 G control. Student's t-
test was carried out (basal vs pre-stimulated).
Fig. 5. Evaluation of cell viability and cell mortality
of CHME-5 Cells. Panel A shows the growth of
CHME-5 cell line (20.000 cells/well) under basal
conditions in plain growth media. The fluorescence
data indicates the not viability cells whereas the lu-
minescence data indicates the viability cells. Panel B
and C show the cell viability and cell mortality re-
spectively in the presence of the indicated CMs. For
each time point the data are expressed relative to the
control, which is taken as 100%. ****p < 0,0001
CM vs basal condition. Two-way ANOVA analysis
was carried out.
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3.5. Effects of mTOR inhibitors on the glioma-microglia paradigm
Under basal conditions, CHME-5 cells express high levels of Raptor
A (major component of mTORC1) and Rictor (a major component of
mTORC2) gene expression. None of the CMs used -regardless of cell
origin or pre-stimulation state-effected that gene expression (data not
shown), nor did incubation with the mTOR inhibitor RAPA modify ei-
ther Raptor and Rictor gene expression in the presence of any of the
CMs (data not shown).
Despite absence of effects on mTOR components, RAPA
(10–100 nM) decreased urea production (Fig. 11) and ARG1 expression
(Fig. 12) from CHME-5 cells exposed to B-CMs or PS-CMs. In addition,
incubation with RAPA had no effects on either IL6, ARG1, or IL10 gene
expression. RAPA increased gene expression of iNOS 4-fold versus iNOS
levels due to the presence of CMs only (data not shown); however that
increase was not associated with any increase in NO levels at 48 h.
These data are consistent with our previous observations in the rat
model (Lisi et al., 2014a), and reinforce the idea that the blockade of
mTOR is associated with a modification of M2/M1 ratio.
4. Discussion
In the present study, we used two different approaches (i.e. human
tumor specimens and human cell models) to study the activation of the
mTOR pathway in glioma-associated microglia. In particular, by im-
munostaining analysis of surgical GBM specimens from 42 patients, we
showed phosphorylated-mTOR expression and localization in micro-
glia-macrophage cells. In addition, these findings were confirmed in
functional experiments. Using U87MG or T98G cells as a model for
human glioma and CHME-5 cells to model human microglia, we in-
vestigated the involvement of mTOR in in vitro paradigms of microglia-
glioma interaction under two different conditions (Figure Suppl 1).
In the last decade, the role of microglia in GBM pathology is be-
coming clearer. Under the influence of GBM, microglia tend to assume a
M2 phenotype, which has predominantly a pro-tumor role. However, in
addition to this role, evidence that is more recent indicates that some
cells with microglial characteristics seen in GBMs are actually part of
the tumor cell population. According to these findings, the expression of
CD163, an M2 microglia marker, is also a marker for fusion hybrids
between immune cells (macrophages or microglia) and neoplastic
tumor cells (Huysentruyt et al., 2011; Lindström et al., 2017; Gast et al.,
2018). In this context, we recently found that in surgical GBM speci-
mens CD163 expression is higher within GBM specimens than in the
surrounding periphery in both male and female patients. (Lisi et al.,
2017a). Taken together these findings lead to the hypothesis that under
specific conditions microglial cells may lose characteristics of the im-
mune system and acquire tumor-cell characteristics. However, addi-
tional studies are required to confirm or negate these possibilities.
In our studies, we used production of urea to serve as an index of
arginine metabolism (an M2 type phenotype). The main source of urea
in eukaryotes is from conversion of arginine to ornithine by the enzyme
arginase. However, urea can also be generated from glutamine via ac-
tion of glutaminase which produces ammonia which can then be con-
densed with CO2 to generate urea (Bach and Smith, 1956); a process
which mainly occurs in liver. However, most glial derived tumor cells
depend upon glutamine for growth (Szeliga et al., 2009; Szeliga and
Albrecht, 2016), associated with expression of a phosphate activated
glutaminase (Majewska et al., 2017) to generate glutamate as an energy
source. It is therefore possibly that treatments of T98G (and U87MG)
cells that modify urea production may be due in part to changes in
phosphate activated glutaminase. Moreover, the suppression of urea
release due to mTOR inhibitors could be due to reductions in gluta-
minase expression, which could contribute to the ability of these in-
hibitors to reduce glioma growth. This would be consistent with find-
ings that up-regulation of glutaminase in certain glioblastoma cell lines
renders them resistant to mTOR inhibition (Tanaka et al., 2015).
Using the human microglia-glioma interaction paradigm, we
showed that the mTOR pathway is fully activated in microglia cells
under conditions mimicking the human GBM pathology. Such mTOR
activation, observed as increases in phosphorylated mTOR fraction, is
in full agreement with data from human tumor specimens, showing that
Fig. 6. Effects of CMs on urea release. Left panel shows the urea content in
CHME-5 cells, under basal condition (white), after U87MG B-CM challenge
(yellow) and after U87MG PS-CM stimulation (blue). Right panel shows the
urea content in CHME-5 cells, under basal condition (white), after T98G B-CM
challenge (yellow) and after T98G PS-CM stimulation (blue). The data are ob-
tained after 48 h of incubation. *, ***p < 0,05 or p < 0,001 respectively vs
control. One-way ANOVA analysis was carried out.
Fig. 7. Effects of CMs on M1 CHME-5. CHME-5 were pre-stimulated with TII for
4 h. After 4 h cytokines were removed, CMs were administrated for the sub-
sequent 48 h and urea content were measured. As indicated in figure boxes 2-3-
4-5-6 were pre-treated with TII, boxes 7-8-9-10 were pre-treated with medium.
*p < 0,05 vs TII CMs. One-way ANOVA analysis followed by Bonferroni's post-
test was carried out.
Fig. 8. Evaluation of iNOS pathway after CMs challenge. CHME-5 were pre-
stimulated with TII for 4 h. After 4 h cytokines were removed, CMs were ad-
ministrated for the subsequent 4 or 24 h and iNOS gene expression were
measured. Panel A show the effects of U87MG CMs on iNOS gene expression in
CHME-5. Panel B show the effects of T98G CMs on iNOS gene expression in
CHME-5. Panel C shows nitrite content in 48-h experiments in CHME-5. White
bar indicates the control group whereas the red bar the TII group.
***p < 0,001 vs control. One-way ANOVA analysis followed by Bonferroni's
post-test was carried out.
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39% of microglia-macrophage in glioma specimens express mTOR
phosphorylated at Ser-2448, taken as marker of mTORC1 activation
(Rosner et al., 2010). In addition, and consistent with previous data
from our group and others, here we show that microglia express an M2
pro-tumor phenotype in the presence of glioma cells, and that this M2
phenotype is down-regulated in the presence of an mTOR inhibitor.
Based on the above data, we hypothesize that the blockade of mTOR in
GBM patients might induce a reduction in M2 phenotype expression in
about 40% of all tumor-associated microglia. In this regard, it is
important to emphasize that microglia may represent 30–70% of the
entire tumor (Wood GW and Morantz, 1979; Roggendorf et al., 1996; da
Fonseca and Badie, 2013).
In the present study, we reported data using two different glioma
cell lines. Preliminary data (Figs. 3 and 4) showed that conditioned
media obtained by U87MG or T98G are similar but not identical in term
of IL6, IL1β and PGE2 release. In fact, CMs obtained from T98G contain
more IL6 and IL1β than that from U87MG but contain less PGE2. These
differences could explain why in some conditions (i.e phospho-mTOR
activation) CMs give different results.
Here we showed that mTOR activation could be elicited through
different pathways, depending on different experimental conditions. In
fact, when CHME-5 cells were treated with B-CM [a condition mi-
micking an early stage of pathology (Lisi et al., 2014b)], the activation
of mTOR pathway was associated with a significant blockade of TSC2.
On the contrary, when CHME-5 cells were exposed to PS-CM [a con-
dition that mimics a late stage of pathology (Lisi et al., 2014b)], mTOR
activation was in part independent from TSC2 inactivation. While TSC2
inhibition is considered as the ‘classical’ pathway of TOR activation,
TSC2-independent mechanisms have also been described. Upstream
oncogenic mutations activate mTORC1 kinase via at least two alter-
native mechanisms: down-regulation/inactivation of TSC2 and phos-
phorylation of the mTORC1 inhibitor PRAS40 by AKT (Huang and
Manning, 2009; Lv et al., 2017). The TSC2 protein integrates signals
from three pathways (AKT, ERK/RSK, and LKB1/AMPK); each of these
pathways can lead to phosphorylation of several serines and threonines
on TSC2. The latter in turn acts as a GTPase-activating protein for the
small Ras-like protein, Rheb. Whereas Rheb bound to GDP is thought to
be inactive, Rheb-GTP is an essential activator for mTORC1 kinase
(Dibble and Cantley, 2015). Phosphorylation of PRAS40 by AKT in-
hibits the binding of PRAS40 to mTORC1 and the subsequent mTORC1
kinase activation (Lv et al., 2017).
Fig. 9. Evaluation of mTOR pathway in in vitro mi-
croglia-glioma interaction. Western blot analysis of
CHME-5 lysates prepared 2 h after the following
treatments: Lane 1, control, 2, U87MG B-CM; 3,
U87MG PS-CM; 4, T98G B-CM; 5, T98G PS-CM; 6,
TII. Panel A shows western blot analysis for phospho-
mTOR Serine 2448 (top image) and total mTOR
(bottom image), panel B shows 4EBP1 quantification
and panel C shows p-P70S6K quantification. *, **,
***p < 0,05 p < 0,01 or p < 0,001 respectively
vs control. One-way ANOVA analysis followed by
Bonferroni's post-test was carried out.
Fig. 10. Evaluation of TSC2 in in vitro microglia-glioma interaction. Western
blot analysis of CHME-5 lysates for TSC2 (top image) and β-actin (bottom
image) prepared 2 h after the following treatments: Lane 1, control; 2, U87MG
B-CM; 3, U87MG PS-CM; 4, T98G B-CM; 5, T98G PS-CM. **, ***,****p < 0,01,
p < 0,001 or p < 0,0001 respectively vs control. One-way ANOVA analysis
followed by Bonferroni's post-test was carried out.
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Because of their availability as immunosuppressive agents, mTOR
inhibitors have been extensively investigated in clinical trials in on-
cology, based on their ability to control cell proliferation. So far, the
efficacy of everolimus (RAD0001) has been demonstrated as a second
line treatment in renal, breast and neuroendocrine cancers of lung,
pancreatic or gastrointestinal origin. Overall, mTOR inhibitors have
had limited success in clinical trials for various other tumor types (in
glioma but also in major solid tumors). The reasons for such limited
success are yet to be clarified, but may be related to the inhibition of a
large number of mTORC1-regulated signaling systems normally in-
volved in tumor suppression, such as the activation of receptor tyrosine
kinases (RTKs), PI3K-Akt signaling, and Ras-ERK pathway (Nussinov
Fig. 11. Effects of rapamycin on urea levels in CHME-5 after stimulation with CMs (48 h experiments). **p < 0,01 vs control; ° p < 0,05 vs CM. One-way ANOVA
analysis followed by Bonferroni's post-test was carried out.
Fig. 12. Effects of rapamycin on ARG1 expression in CHME-5 after stimulation with CMs (24 h experiments). Panel A, control; B, B-CM; C, B-CM + Rapa 100 nM; D,
PS-U87; E, PS-U87 + Rapa 10 nM; F, B-T98; G, B-T98 + Rapa 10 nM; H, PS-T98; I, Ps-T98 + Rapa 10 nM.
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et al., 2018). In order to overcome these limitations, alternative stra-
tegies have been explored in the past few years and a number of ATP-
competitive mTOR inhibitors have been developed, which block both
mTORC1 and mTORC2 activity. Unlike RAPA, which is a specific al-
losteric inhibitor of mTORC1, these ATP-competitive inhibitors target
the catalytic site of the enzyme, thus promoting a broader, more potent
and sustained inhibition of mTOR, thereby preventing the activation of
PI3K/Akt caused by the de-repression of negative feedbacks (Martelli
et al., 2018). In addition, it is important to consider that glucose and
glutamine are drivers of mTOR activation (Tanaka et al., 2015) and in
particular, glucose drives GBM through the PI3K-AKT pathway (Shukla
et al., 2018). Therefore another possible way to escape the limited
success of mTOR inhibitor in clinical trials could be use therapies that
target glucose and glutamine to affect the mTOR pathway. However,
while the inhibition of mTOR pathway remains a meaningful target for
the treatment of GBM, novel and more specific molecules are needed.
In conclusion, a main finding of this study the observation that the
mTOR pathway is activated in 39% of microglia-macrophage within
GBM tumors, compared to 21% in peripheral tissues. We also showed
that pharmacological inhibition of mTOR reduce urea levels and ARG1
expression -taken as a M2 marker-in in vitro models of both early- and
late stage glioma. Since the M2 profile of microglial activation is widely
thought to be associated to tumor progression (Annovazzi et al., 2018),
the increase in the ratio of M1 microglia bearing cytotoxic and anti-
tumor activity brought about by mTOR inhibition might be envisioned
as an additional antitumor mechanism of mTOR inhibitors, along with
direct anti-proliferative activity.
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